Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn’s disease—the devil is in the detail

Ashish Srinivasan, Peter De Cruz, Daniel R. van Langenberg

Research output: Contribution to journal › Letter › Other › peer-review

Original language	English
Pages (from-to)	561-562
Number of pages	2
Journal	Alimentary Pharmacology and Therapeutics
Volume	52
Issue number	3
DOIs	https://doi.org/10.1111/apt.15862
Publication status	Published - 1 Aug 2020

Access to Document

@article{9b9937092cae4a3fb5fae780c511c849,

title = "Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn{\textquoteright}s disease—the devil is in the detail",

author = "Ashish Srinivasan and {De Cruz}, Peter and {van Langenberg}, {Daniel R.}",

year = "2020",

month = aug,

day = "1",

doi = "10.1111/apt.15862",

language = "English",

volume = "52",

pages = "561--562",

journal = "Alimentary Pharmacology & Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Letter

T2 - choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn’s disease—the devil is in the detail

AU - Srinivasan, Ashish

AU - De Cruz, Peter

AU - van Langenberg, Daniel R.

PY - 2020/8/1

Y1 - 2020/8/1

UR - http://www.scopus.com/inward/record.url?scp=85087768833&partnerID=8YFLogxK

U2 - 10.1111/apt.15862

DO - 10.1111/apt.15862

M3 - Letter

C2 - 32656826

AN - SCOPUS:85087768833

VL - 52

SP - 561

EP - 562

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

SN - 0269-2813

IS - 3

ER -